Remove Food and Drug Administration Remove Patients Remove Physicians Remove Transportation
article thumbnail

Lexicon gets FDA approval for Inpefa to treat heart failure

Pharmaceutical Technology

Lexicon Pharmaceuticals (Lexicon) has received approval from the US Food and Drug Administration (FDA) for its Inpefa drug to treat heart failure. Inpefa is a once-daily oral tablet indicated as an inhibitor of sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1).

article thumbnail

Delivery systems for biologics

European Pharmaceutical Review

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS

Pharmaceutical Technology

Ipsen has received US Food and Drug Administration (FDA) approval for Bylvay (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome (ALGS). More than 90% of patients who received treatment with odevixibat were pruritus responders.

article thumbnail

Clinical Research News: Social Determinants Of Health Data Help Identify Sites For Trials

Clarify Health

Earlier this year, Clarify Health began offering a new service ( Clarify Trials ) whereby companies could receive a list of the most-ideal sites for studies tied to the characteristics of patients they hope to enroll. It essentially offered an assessment of risk that would initially be available to care-planning clinicians.

article thumbnail

Clinical Research News: Social Determinants Of Health Data Help Identify Sites For Trials

Clarify Health

Earlier this year, Clarify Health began offering a new service ( Clarify Trials ) whereby companies could receive a list of the most-ideal sites for studies tied to the characteristics of patients they hope to enroll. It essentially offered an assessment of risk that would initially be available to care-planning clinicians.

article thumbnail

Readjusting the Life Sciences Industry’s Approach to Improving Adherence

PM360

Addressing the issue of medication adherence begins before a patient even fills their first prescription. According to a recent IQVIA analysis, only one in four patients who were new to a brand in 2021 successfully initiated therapy. “To The caveat: only 8% of patients have ever used these hubs, according to research from Phreesia. “As

article thumbnail

MedWand Solutions Receives FDA 510k Clearance

Legacy MEDSearch

By facilitating a more comprehensive assessment of a patient’s health and an extensive remote diagnosis, MedWand provides the crucial missing link in the delivery of telemedicine. Food and Drug Administration (FDA) has granted 510(k) clearance to the MedWand,” shared MedWand CEO and Co-Founder, Robert Rose. “As

FDA 52